Clinical Trials Logo

Clinical Trial Summary

Obesity has been increasing all over the world. This has lead to a significant increase of a liver disease in children called non-alcoholic fatty liver disease (NAFLD). NAFLD is a liver disease that ranges from excess fat being stored in the liver to an inflamed and fatty liver with fibrosis to cirrhosis. NAFLD is thought to be caused by changes in energy, fat and carbohydrate metabolism induced by diets high in in processed foods. Sugary (especially high fructose corn syrup or HFCS) and fatty foods in processed foods have been shown to produce more insulin resistance, a factor that is thought to cause a fatty liver. Currently the main treatment for NAFLD is weight loss. However, it unknown the best way to achieve this. The investigator has shown previously that adolescents with NAFLD eat a lot of fatty and sugary foods, and that when they decrease the amount of foods they eat that contain HFCS, experience some improvements in insulin resistance and liver dysfunction even when they don't lose weight. The plan is to compare and contrast how two different diets (high vs low HFCS containing diets) may affect how much fat gets deposited in the liver and whether or not a lower diet in HFCS can help decrease liver damage in adolescents with NAFLD.


Clinical Trial Description

Study Rationale: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease estimated to occur in 10-20% of obese children and adults. High fructose and saturated fat intakes are thought to be major dietary factors contributing to over nutrition, insulin resistance, cardio-metabolic risk (e.g dysplipidemia, hypertension) and disease pathogenesis in adults and children with NAFLD . Although weight loss is the goal of treatment, there are currently no evidence based clinical guidelines regarding the specific dietary treatment needed for NAFLD. The investigator has shown previously that children and adolescents with NAFLD have diets rich in both total fructose (>10% of total energy intake) and high fructose corn syrup (20-50% of total fructose intake. These levels of intake were associated with increasing indices of liver dysfunction, insulin resistance and inflammation. In a recent pilot study, the investigator has showed that children with NAFLD experienced significant reductions in systolic blood pressure, percentage body fat, plasma markers of liver dysfunction (ALT, AST), cardio-metabolic risk (HOMA-IR, AI-IR, TG, Apo-B100) and alterations in body fat distribution in response to six months of an iso-caloric/low fructose diet (~5% of total kcal). High levels of fructose in the diet have been independently associated with insulin resistance, visceral adiposity, hepatic and skeletal muscle intramyocellular fat (IMF) deposition, altered hepatic mitochondrial function and energy utilization (ATP depletion), increased rates of de novo lipogenesis, inflammation, and hepatic fibrosis in both animal models and adults with NAFLD. While adult studies in NAFLD have related the impact of high intakes of HFCS to altered liver energetics (ATP production) and increasing insulin resistance and IMF , this has not be studied in obese children and adolescents with NAFLD. In addition, no information is available regarding the impact of dietary fructose reductions on these processes in either obese children, adolescents or adults with NAFLD. The plan is to use validated, non-invasive and safe methodologies such as Magnetic Resonance Imaging (MRI) and Magnetic Resonance Stimulation (MRS) to compare and contrast the effects of varying fructose intakes (low vs high) in iso-caloric diets on liver mitochondrial energetic (ATP production), hepatic and skeletal muscle fat content and markers of cardio-metabolic risk, liver dysfunction, insulin resistance, inflammation and oxidative stress in adolescents with NAFLD. Hypotheses 1. Obese adolescents with NAFLD treated with a low fructose /low HFCS diet over 12 weeks, in the absence of weight loss, will result in significant improvements in indices of hepatic ATP production and reduced liver/ skeletal muscle fat deposition when compared to the effects of a higher fructose/higher HFCS diet. 2. Obese adolescents with NAFLD treated with a low fructose /low HFCS diet over 12 weeks, in the absence of weight loss, will result in significant improvements in indices of visceral and subcutaneous adiposity, insulin resistance and markers of liver and cardio-metabolic dysfunction, inflammation and oxidative stress when compared to the effects of a higher fructose/higher HFCS diet. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05528471
Study type Interventional
Source University of Alberta
Contact Diana R Mager, PhD RD
Phone 780-492-7687
Email mager@ualberta.ca
Status Recruiting
Phase N/A
Start date April 30, 2015
Completion date December 30, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05480696 - Soluble Fibre Supplementation in NAFLD Phase 1
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Completed NCT04671186 - Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan N/A
Recruiting NCT05979779 - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis Phase 2
Recruiting NCT05462353 - Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH Phase 2
Completed NCT05006885 - ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) Phase 1
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Recruiting NCT04365855 - The Olmsted NAFLD Epidemiology Study (TONES) N/A
Recruiting NCT05618626 - Prevention of NAFLD and CVD Through Lifestyle Intervention N/A
Completed NCT03256526 - 6-week Safety and PD Study in Adults With NAFLD Phase 2
Enrolling by invitation NCT06152991 - Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy Phase 3
Completed NCT03681457 - Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects Phase 1
Completed NCT06244550 - Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors N/A
Not yet recruiting NCT05120557 - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH N/A
Completed NCT03060694 - Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
Completed NCT02526732 - Hepatic Inflammation and Physical Performance in Patients With NASH N/A
Recruiting NCT01988441 - The Influence of Autophagy on Fatty Liver
Recruiting NCT01680003 - Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease Phase 2
Completed NCT01712711 - Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease Phase 2
Recruiting NCT00941642 - Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Phase 4